The future of drug discovery is AI-powered, and North America is leading the way with early investments, cutting-edge AI, and biotech infrastructure. Powered by IPA, BioStrand, and Talem, MindWalk blends AI, data, and lab science. Learn more: https://t.co/KUIvzVTgXN 🇺🇸

Biostrand new websites $IPA #artificialintelligence #drugdiscovery #innovation #biotech #AI #LLMs #bioinformatics #HYFTs #Universalfingerprints https://t.co/DprJn89yaW

Catalysts for $IPA - 𝗙𝗗𝗔 𝗽𝗵𝗮𝘀𝗲𝘀 𝗼𝘂𝘁 𝗮𝗻𝗶𝗺𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 - Biostrand (AI) growth 136 % - Entered into a USD $8M–$10M partnership - AI-Designed GLP-1 Peptides

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenomic Recommendations Using LENSᵃⁱ™ "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict

Active Small Caps Pre-Market $IPA - ImmunoPrecise Antibodies Ltd. 🇨🇦 Sector: Healthcare - Biotechnology Market Cap: 15.31M Float: 20.47M News: ImmunoPrecise Antibodies Ltd. launched its AI-powered BioStrand pipeline to revolutionize drug discovery, combining advanced AI with

$IPA- $2.10 IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

BioStrand (an IPA subsidiary) and InterSystems announce they have entered a collaboration to combine technologies to integrate the new vector search capability of the InterSystems IRIS® data platform with BioStrand's LENSᵃⁱ™ platform, setting a new standard for AI-driven

$IPA @ImmunoPrecise Cro is growing, 21% last qtr, the #Ai Hyfts will add to the franchise’s growth. The Hyfts definitely differentiate us from the competition. Our top CRO client base are eager to begin using the Biostrand Operating System. This will lead to more efficient 🧵

$IPA Going | Float: 21.6M | IO: 7.11% - IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology.

Could they be related — like father and son? They both came from Biostrand, and even their last names match. $HYFT

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR). BioStrand is leveraging their patented Foundation AI Model, LENSᵃⁱ™, by applying advanced Large Language Models (LLM) to capture real world data from Electronic

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery. The launch, led by Dr. Dirk Van Hyfte, highlights the integration of BioStrand's LENSᵃⁱ™, powered

Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Platform API by BioStrand (IPA subsidiary). This game-changing API plugs directly into large pharma or biotech existing platforms, transforming their ability to

$IPA IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology https://t.co/IaqcGfBKiM

Big week at the highly anticipated NVIDIA conference, where Team IPA - comprising Dr. Jennifer Bath, IPA CEO, Dr. Dirk Van Hyfte, BioStrand Head of Innovation, and Frederic Chabot, IPA Head of Corporate Development - look forward to meeting to share the latest breakthrough

$IPA - Immunoprecise Antibodies 🔹Subsidiary BioStrand, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery 🔹Low float/ OS near 26M shares 👆 0% PreM/ $0.99

Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”. Today, IPA (ImmunoPrecise Antibodies), along with BioStrand and Talem, unify under a single identity: MindWalk. This evolution marks more than a name change. It reflects a strategic

IPA's subsidiary, BioStrand, and its advanced AI Integrated Intelligence platform, LENSᵃⁱ™, are now making their mark in the world with companies that provide database management systems. We're honored to receive recognition from InterSystems, an innovative data technology

Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdiscovery. Dirk Van Hyfte, BioStrand's Head of Innovation and Tom Dyar of InterSystems discuss the integration of BioStrand's LENSᵃⁱ Integrated Intelligence